x
x
Disclaimer

The U.S. section of Abbottep.com is a product-specific website that is NOT intended for non U.S. residents. This web content is exclusively reserved for health care professionals in the United States.

Do you wish to continue to visit the Abbottep.com U.S. section?

Get your rhythm back.

Serious heart rhythm disorders called arrhythmias, affect the lives of millions of people daily. Unfortunately, most treatments for these conditions are generic and one-size-fits-all, with mixed results.


But there’s hope.


We believe there is a better way to treat serious heart rhythm disorders such as atrial fibrillation and ventricular tachycardia. Using Abbott Electrophysiology’s technology, doctors can identify the sources of arrhythmias that are unique to each person. Now treatment can be tailored to your individual needs.


Find Your Source.
Get Tailored Therapy.
Get Your Rhythm Back.

Find a doctor near you who is using the Topera Rotor Mapping System

The most common heart rhythm disorder, atrial fibrillation (AF, or afib) is a serious global public health problem which affects millions of people around the world. If left untreated, AF doubles the risk of heart-related deaths and also increases stroke risk by up to 500%. Unfortunately, although it is such a serious health problem, AF has historically been difficult to treat with an acceptable degree of success.

In response to this unaddressed need, Abbott, Inc. has developed a unique 3D analysis and mapping solution (the Abbott 3D Mapping System), which consists of the RhythmView Workstation and FIRMap diagnostic catheter. The Abbott 3D Mapping System has been designed to enable physicians to view the electrical activity of the heart, thereby supporting the diagnosis and patient-specific treatment planning for a variety of heart arrhythmias including atrial fibrillation, atrial flutter, atrial tachycardia, and ventricular tachycardia.

The Abbott 3D Mapping System received FDA clearance in 2013 and is now in routine use at several leading medical centers throughout the United States.

Rotor mapping and Ablation in Redo-Cases of PeAF Patients

Rotor mapping and Ablation in Redo Cases of Persistent Atrial Fibrillation Procedural and Follow-up Data1

Patent Characteristics:

This is a study consisting of 54 patients with persistent AF, all of which had failed a prior conventional ablation (a mean of 1.4 prior ablations).

The follow-up period was 12 months.

Study findings:

The location and distribution of rotors identified and long-term results were consistent with previously published results of FIRM-guided ablation.234

  • Most rotors were outside of the areas that would normally be targeted with traditional ablation.
  • The presence of RA rotors was seen in over 50% of patients, which reinforces the importance of the RA.
  • AF acutely terminated in only 5 patients, therefore reinforcing the value of rotor elimination as an acute endpoint.

Copies of published articles and RhythmView® labeling are available on request. Any questions regarding the publications or clinical use of RhythmView Workstation should be directed to our medical affairs team.


  1. Spitzer, Karolyi, Rammler, Scharfe, Weinmann, Otto, Langbein Rotor mapping and Ablation in Redo-Cases of Persistent Atrial Fibrillation Procedural and Follow-up Data. 2016 AF Symposium: poster presentation
  2. Narayan SM, Krummen DE, Shivkumar K, Clopton P, Rappel W-J, Miller J. Treatment of atrial fibrillation by the ablation of localized sources: The Conventional Ablation for Atrial Fibril-lation With or Without Focal Impulse and Rotor Modulation: CONFIRM Trial. JAmCollCardiol.2012;60(7):628–636.
  3. Narayan SM, Clopton P, Krummen DE, Shivkumar K, Miller J. Direct or coincidental ablation of localized sources may
    explain the success of atrial fibrillation ablation. On-treat-ment analysis from the CONFIRM trial. J Am Coll Cardiol.
    2013;62(2):138–147.
  4. Miller JM, Kowal RC, Swarup V, et al. Initial independent outcomes from focal impulse and rotor modulation ablation for
    atrial fibrillation: Multicenter FIRM registry. J Cardiovasc Electrophysiol. 2014;25(9):921–929.